Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more

Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more Aurobindo Pharma terminated an agreement to acquire a majority stake in Cronus Pharma after the proposal stoked capital allocation concerns

No comments:

Post a Comment